Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of daily subcutaneous metreleptin in familial partial lipodystrophy
MOH_2023-03-26_012474Phase 3Not yet recruiting
- Sponsor
- Amryt Pharma
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial partial lipodystrophy (FPLD) comparing Myalepta with Placebo (2 arms). Planned start Mar 2023; status: not yet recruiting.
02
Drugs
metreleptin
03
Conditions
familial partial lipodystrophy (FPLD)
Beyond the preview
Go deeper on MOH_2023-03-26_012474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-26_012474.